Research programme: Parkinson's disease therapeutics - Proximagen/Upsher-Smith

Drug Profile

Research programme: Parkinson's disease therapeutics - Proximagen/Upsher-Smith

Alternative Names: PRX-1; PRX-1235; PRX-2; PRX-5

Latest Information Update: 15 Aug 2012

Price : $50

At a glance

  • Originator Proximagen Neuroscience
  • Developer Boehringer Ingelheim; Proximagen; Upsher-Smith
  • Class
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Neuropathic pain; Parkinson's disease

Most Recent Events

  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 27 Jul 2005 Preclinical trials in Parkinson's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top